LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Aperta

3.69 5.43

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.45

Massimo

3.75

Metriche Chiave

By Trading Economics

Entrata

44M

-26M

Vendite

-5.8M

42M

Margine di Profitto

-61.388

Dipendenti

550

EBITDA

44M

-22M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+16.28% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

162M

1.2B

Apertura precedente

-1.74

Chiusura precedente

3.69

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 dic 2025, 23:21 UTC

Utili
Acquisizioni, Fusioni, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dic 2025, 23:14 UTC

Acquisizioni, Fusioni, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dic 2025, 22:01 UTC

I principali Market Mover

Costco Wholesale Reports Higher Monthly Sales

3 dic 2025, 21:38 UTC

Utili

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dic 2025, 23:59 UTC

Discorsi di Mercato

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dic 2025, 23:49 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 dic 2025, 23:49 UTC

Discorsi di Mercato

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dic 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dic 2025, 23:13 UTC

Discorsi di Mercato

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dic 2025, 23:10 UTC

Utili

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dic 2025, 23:08 UTC

Discorsi di Mercato

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dic 2025, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dic 2025, 22:59 UTC

Acquisizioni, Fusioni, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dic 2025, 22:45 UTC

Discorsi di Mercato

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dic 2025, 22:20 UTC

Utili

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dic 2025, 22:19 UTC

Utili

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dic 2025, 22:17 UTC

Utili

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dic 2025, 22:16 UTC

Utili

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dic 2025, 22:15 UTC

Utili

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dic 2025, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dic 2025, 22:09 UTC

Acquisizioni, Fusioni, Takeovers

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dic 2025, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

3 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

3 dic 2025, 21:49 UTC

Utili

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:23 UTC

Utili

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dic 2025, 21:19 UTC

Utili

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:06 UTC

Utili

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:04 UTC

Utili

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dic 2025, 21:04 UTC

Utili

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dic 2025, 21:03 UTC

Utili

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Confronto tra pari

Modifica del prezzo

Maravai LifeSciences Holdings Inc (Class A) Previsione

Obiettivo di Prezzo

By TipRanks

16.28% in crescita

Previsioni per 12 mesi

Media 4 USD  16.28%

Alto 4 USD

Basso 4 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Maravai LifeSciences Holdings Inc (Class A) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.02 / 2.115Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat